Skip to main content

The Globe and Mail

Paladin acquires Dimethaid unit with Pennsaid licence

Paladin Labs Ltd. has acquired Dimethaid Health Care Ltd., which owns the Canadian licence for Pennsaid, a lotion to treat osteoarthritis in the knee. Montreal-based Paladin said it paid the parent company, Dimethaid Research Inc., an undisclosed upfront payment. Markham, Ont.-based Dimethaid will also receive a share in operating profit above minimum targets and a long-term supply accord for the lotion, which is expected to generate sales of $8-million to $9-million by the end of 2005, Paladin said. DMX (TSX) rose 0.5 cents to 26 cents. PLB (TSX) fell 15 cents to $5.20.

Report on Business Company Snapshots are available for:
Report an error Licensing Options
Comments

The Globe invites you to share your views. Please stay on topic and be respectful to everyone. For more information on our commenting policies and how our community-based moderation works, please read our Community Guidelines and our Terms and Conditions.

Please note that our commenting partner Civil Comments is closing down. As such we will be implementing a new commenting partner in the coming weeks. As of December 20th, 2017 we will be shutting down commenting on all article pages across our site while we do the maintenance and updates. We understand that commenting is important to our audience and hope to have a technical solution in place January 2018.

Discussion loading… ✨